Trigeminal Neuralgia Treatment Market Report 2026

The trigeminal neuralgia treatment market size has grown strongly in recent years. It will grow from $0.73 billion in 2025 to $0.78 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing diagnosis rates of trigeminal neuralgia, reliance on pharmacological pain management, expansion of neurology specialty services, improved imaging for nerve disorders, growing availability of surgical treatment options.

The trigeminal neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $1 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for durable pain relief solutions, rising adoption of gamma knife radiosurgery, expansion of outpatient surgical centers, growing focus on patient quality-of-life outcomes, advancements in neurosurgical techniques. Major trends in the forecast period include increasing use of advanced anticonvulsant medications, rising adoption of minimally invasive surgical procedures, growing preference for stereotactic radiosurgery, expansion of multidisciplinary pain management approaches, enhanced focus on long-term symptom control.

The increasing prevalence of neurological disorders is expected to drive the growth of the trigeminal neuralgia treatment market in the coming years. Neurological disorders include a wide range of conditions that affect the brain, spinal cord, and peripheral nerves. This rise is largely attributed to the aging population, as advancing age increases the risk of disorders such as Alzheimer’s disease, Parkinson’s disease, and stroke. Treatments for trigeminal neuralgia support patients by alleviating severe facial pain, minimizing nerve irritation, improving quality of life, and helping prevent further neurological complications. For example, in March 2023, the Alzheimer’s Association reported that around 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with projections indicating this number could reach 13.8 million by 2060. As a result, the growing burden of neurological disorders is contributing to the expansion of the trigeminal neuralgia treatment market.

The expanding geriatric population is expected to propel the growth of the trigeminal neuralgia treatment market in the coming years. The geriatric population typically includes individuals aged 65 years and above, a group often associated with higher healthcare needs due to age-related physiological changes, chronic conditions, and functional limitations. Growth in this population is driven by increased life expectancy, advances in healthcare, declining birth rates, improved living standards, better disease management, reduced infant mortality, enhanced nutrition, and greater access to medical innovations. Trigeminal neuralgia treatments benefit older adults by reducing severe facial pain, improving daily functioning, and enhancing overall quality of life. For instance, in October 2024, the World Health Organization reported that the global population aged 60 and above is projected to reach 1.4 billion by 2030, accounting for one in six people worldwide. This number is expected to double to 2.1 billion by 2050, with those aged 80 and above projected to triple to 426 million. Consequently, the aging population is a key driver of growth in the trigeminal neuralgia treatment market.

Leading companies in the trigeminal neuralgia treatment market are concentrating on the development of innovative approaches, such as minimally invasive nerve ablation, to enhance patient outcomes, reduce procedure-related risks, and improve quality of life for individuals experiencing chronic facial pain. Minimally invasive nerve ablation is a procedure that uses heat, cold, or chemical agents to selectively disrupt pain-causing nerves while minimizing damage to surrounding tissues. For example, in August 2025, NeuroOne Medical Technologies Corporation, a U.S.-based medical technology company, received approval from the U.S. Food and Drug Administration (FDA) for its OneRF Trigeminal Nerve Ablation System for the treatment of trigeminal neuralgia. The system utilizes a multi-contact radiofrequency probe that allows precise pain localization, stimulation, and customized ablation through a single electrode. It incorporates temperature-controlled lesioning to enhance accuracy and safety, potentially shortening procedure time and improving patient comfort. This minimally invasive system delivers targeted radiofrequency energy to ablate nerve fibers responsible for chronic facial pain, including trigeminal neuralgia.

Major companies operating in the trigeminal neuralgia treatment market are Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Elekta, Accuray Inc., UCB S.A., Eli Lilly and Company.

North America was the largest region in the trigeminal neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the trigeminal neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the trigeminal neuralgia treatment market by increasing costs of imported neurological drugs, surgical instruments, radiosurgery systems, and diagnostic imaging equipment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported medical devices, while Asia-Pacific faces higher capital equipment costs. These tariffs are increasing procedural expenses and treatment pricing. However, they are also encouraging domestic production of neurosurgical tools, regional device manufacturing, and localized supply chains for neurological care equipment.

The trigeminal neuralgia treatment market research report is one of a series of new reports that provides trigeminal neuralgia treatment market statistics, including trigeminal neuralgia treatment industry global market size, regional shares, competitors with a trigeminal neuralgia treatment market share, detailed trigeminal neuralgia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the trigeminal neuralgia treatment industry. This trigeminal neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Trigeminal neuralgia treatment focuses on medical approaches to manage the intense, sudden facial pain associated with trigeminal neuralgia, a condition affecting the trigeminal nerve. The primary objective of treatment is to relieve pain, lessen the frequency and severity of attacks, and address the underlying nerve irritation, thereby improving the patient’s quality of life.

The main categories of trigeminal neuralgia treatment include medications, surgical interventions, and others. Medications are drugs or compounds developed to treat trigeminal neuralgia by reducing pain through the regulation of nerve activity. These treatments are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by multiple end users, including hospitals, specialty clinics, ambulatory surgical centers, and others.

The trigeminal neuralgia treatment market consists of revenues earned by entities by providing services such as physical therapy, patient education, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The trigeminal neuralgia treatment market also includes sales of anticonvulsants, muscle relaxants, and tricyclic antidepressants (TCAs). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.